Q2 2026 Xtant Medical Holdings Inc Earnings Call Transcript

Aug 11, 2026 / 12:30 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Successfully integrated the Dillon sales team, expanding the commercial organization to over 25 reps and adding national accounts expertise.
Launched Trivium Shaped, which is showing strong early sales traction and complements recent product launches like Collagen X and OsteoFactor Pro.
The Dillon distribution agreement provides entry into a $1 billion hemostatic products market, with Hemoblast sales already contributing $1.5 million in Q2.
Expanded product portfolio positions Xtant to address a combined TAM of approximately $7.5 billion across regenerative medicine, chronic wound care, and surgical repair.
Expects significant sales synergies from cross-selling as the new specialty reps gain familiarity with the broader product line, driving accelerating biologics growth in Q3 and beyond.

Negative

Total revenue declined to $23 million in Q2 2026 from $35.4 million in Q2 2025, with pro forma revenue also down due to headwinds in the amnio product line.
Gross margin fell to 57.9% from 68.6% year-over-year, impacted by the cessation of Q-Code license revenue and increased excess inventory charges.
Net loss of $9.4 million in Q2 2026, compared to net income of $3.6 million in the prior year, with adjusted EBITDA turning negative.
Revenue guidance for full-year 2026 was reduced to $99-$103 million from $101-$105 million due to lower-than-expected biologics revenue and persistent amnio headwinds.
The integration of new sales reps and transition of Hemoblast purchase orders to Xtant took longer than expected, limiting revenue recognition and contributing to soft Q2 sales.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

XTNT.A - Xtant Medical Holdings Inc
Q2 2026 Xtant Medical Holdings Inc Earnings Call
Aug 11, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everyone, and welcome to the Exstant Medical Second Quarter 2026 Financial Results Conference Call.

At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation.

Please note that this conference is being recorded.

I will now turn the conference over to your host, Kevin Gardner of LifeSci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and welcome to Exstant Medical's second quarter 2026 financial results call.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.